China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Mar 29, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on improving the diagnosis and treatment of type 2 inflammatory skin diseases, such as atopic dermatitis eczema and prurigo nodularis. The goal is to gather information about how patients are currently being treated and to evaluate how well different treatments work and how safe they are. By doing this, the researchers hope to enhance the overall care provided to individuals suffering from these skin conditions.

To participate in this trial, patients must be diagnosed with one of the specified skin diseases and come from certain medical centers that are approved for the study. Participants will be asked to provide informed consent and may need to complete questionnaires about their condition. The trial is currently recruiting patients of all ages and genders. If you or a loved one has one of these skin conditions, this trial may provide an opportunity to contribute to advancing treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details);
• • 2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis).
• Exclusion Criteria:
• • 1. patients who fail to provide informed consent form;
• • 2. patients who cannot complete the questionnaire independently or under the guidance of investigators